VIVUS to Present at the 2013 JP Morgan Healthcare Conference

VIVUS to Present at the 2013 JP Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 4, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc.
(Nasdaq:VVUS) today announced that Leland Wilson, Chief Executive Officer,
will present an overview of the Company at the 31^st Annual JP Morgan
Healthcare Conference.

The VIVUS presentation will take place at the Westin St. Francis Hotel in San
Francisco, CA on Monday, January 7, 2013 at 2:30 p.m. PST. A live webcast and
30-day archive of the presentation will be available at http://ir.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity, sleep
apnea, diabetes and sexual health for U.S., Europe and other world markets.
Qsymia is also in phase 2 clinical development for the treatment of type 2
diabetes and obstructive sleep apnea.For more information about the company,
please visit www.vivus.com.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should," among
others. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. VIVUS does
not undertake an obligation to update or revise any forward-looking
statements. Investors should read the risk factors set forth in VIVUS' Form
10-K for the year ending December 31, 2011, and periodic reports filed with
the Securities and Exchange Commission.


CONTACT: VIVUS, Inc.
         Timothy E. Morris
         Chief Financial Officer
         morris@vivus.com
        
         Media Relations:
         GolinHarris
         Ashley Buford
         abuford@golinharris.com
         212-373-6045
        
         Investor Relations:
         The Trout Group
         Brian Korb
         bkorb@troutgroup.com
         646-378-2923